Stock Financial Ratios

MGEN / Miragen Therapeutics financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.57
Volume102,000.00
Market Cap ($M)120.47
Enterprise Value ($M)-39.73
Book Value ($M)-0.33
Book Value / Share-0.02
Price / Book3.14
NCAV ($M)7.43
NCAV / Share3.94
Price / NCAV1.53
Income Statement (mra) ($M)
Revenue3.34
EBITDA-12.51
Net Income-12.67
Balance Sheet (mrq) ($M)
Cash & Equivalents42.80
Cash / Share59.33
Assets0.00
Liabilities8.10
Quick Ratio1.61
Current Ratio1.62
Management Effectiveness (mra)
Return on Invested Capital (ROIC)38.88
Return on Assets (ROA)-1.71
Return on Equity (ROE)38.88
Identifiers and Descriptors
CUSIP60463E103
Central Index Key (CIK)1590750
Industry Groups
SIC 8071 - Medical Laboratories
Other Related CUSIPS
826640203
826640104
Share Statistics
Common Shares Outstanding21,370,063
Common Stock Shares Outstanding742,293
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Accounts Receivable Per Share0.03
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Per Share0.00
Assets Current Per Share2.17
Liabilities Per Share0.38
Cash And Equivalents Per Share2.00
Assets Other Non Current Per Share0.00
Debt Per Share4.39
Cash Per Share59.33
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Current Per Share0.00
Equity Per Share1.82
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00

Peers - Medical Laboratories (8071)

Related News Stories

BRIEF-Miragen Therapeutics Prices Public Offering Of Common Stock

2018-02-09 reuters
* MIRAGEN THERAPEUTICS INC <- ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 7 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.50 PER SHARE​ Source text for Eikon: Further company coverage: (43-0)

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

2018-02-06 seekingalpha
Today we will discuss AMAG Pharmaceuticals (AMAG), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia (IDA) who are intolerant of or have not responded adequately to oral iron therapy. (335-5)

Biotech Forum Daily Digest For February 3rd

2018-02-04 seekingalpha
The biotech sector is plummeting with the rest of the market this week trapped within a 'hiccup' that hits equities from time to time. (195-2)

Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space

2018-02-01 seekingalpha
At Stockmatusow, we look for developmental biotech companies we believe provide a legitimate chance at long-term large alpha potential. These factors include, but are not limited to; (60-0)

Miragen (NASDAQ:MGEN) Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst | Benzinga

2018-01-31 benzinga
Miragen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotech company, has product candidates for hematologic cancers and fibrotic diseases in its pipeline. (43-0)

CUSIP: 60463E103